Abstract: Protein S is a significant neuroprotectant when administered after focal ischemic stroke and prevents hypoxic/re-oxygenation injury. Purified human plasma-derived or recombinant protein S improves motor neurological function after stroke, and reduced brain infarction and edema. Protein S also enhances post-ischemic reperfusion and reduced brain fibrin and neutrophil deposition. Cortical neurons are protected from hypoxia/re-oxygenation-induced apoptosis. Thus, protein S and variants thereof are prototypes of a class of agents for preventing injury of the nervous system. In particular, a disease or other pathological condition (e.g., stroke) may be treated with such agents having one or more protein S activities (e.g., anti-thrombotic and anti-inflammatory activities, direct cellular neuronal protective effects) although the latter activities are not be required.

Abstract: A soluble derivative of low-density lipoprotein receptor related protein-1 (sLRP-1) binds directly to Alzheimer's amyloid-? peptide (A?). This binding may be used to detect A? or to separate A? from the rest of a subject's body. In Alzheimer's disease, it may be used to provide diagnostic results by detecting A?, treatment by removing A?, or both.

Abstract: A soluble derivative of low-density lipoprotein receptor related protein-1 (sLRP-1) binds directly to Alzheimer's amyloid-? peptide (A?). This binding may be used to detect A? or to separate A? from the rest of a subject's body. In Alzheimer's disease, it may be used to provide diagnostic results by detecting A?, treatment by removing A?, or both.